The UCL spinout has set the pricing range at $15 to $17 and stands to raise nearly $144m in proceeds if underwriters take up their 30-day option.
Autolus, a UK-based cancer-focused biopharmaceutical spinout from University College London (UCL), on Friday set its pricing shares for an initial public offering on Nasdaq at $15 to $17.
The spinout will offer 7.8 million American Depositary Shares (ADSs), representing the same number of ordinary shares, to raise between $117m and $133m. The IPO could rise to nearly $144m if underwriters take up their 30-day option to purchase an additional 1.2 million ADSs.
Founded in 2014, Autolus is developing a range…
